More than 350 cancer genes have been identified to date (see www.sanger.ac.uk/genetics/CGP) using a combination of epidemiological, genetic, and laboratory techniques. Decades of research into cancer genes have established some basic principles of tumorigenesis, including the roles of tumor suppressor genes and oncogenes, the loss and gain of which, whether through copy number changes or through inactivating or activating point mutations, can initiate or promote the evolution of cancer.
Building on these principles, technologies that permit rapid sequencing or simultaneous analysis of copy number changes in hundreds of thousands of genes, coupled with advanced statistical analysis, are leading to rapid identification of new candidate cancer genes in a large spectrum of human tumors.
Many cancer genes have been identified through the use of positional cloning to characterize a recurrent chromosomal anomaly such as a translocation (t) or a chromosome gain or loss. 1 Other responsible genes, principally those associated with inherited cancer syndromes, have been uncovered through a combination of epidemiological studies and linkage analysis. Finally, a subset of cancer genes has been identified in the laboratory based on homology to other known genes and/or biological characteristics. High-throughput sequencing 2 and microarray 3 platforms that exploit the genetic changes (such as mutations and copy number loss or gain) involved in tumorigenesis promise to accelerate advances in this field.
Chromosome Translocations and Tumorigenesis
Historically, cytogenetic observations have enabled cancer gene discovery. In 1956, the human karyotype was defined as containing 46 chromosomes, which were classified according to size and centromeric position. 4 Several years later, Peter Nowell and David Hungerford identified an abnormal chromosome in patients with chronic myeloid leukemia (CML), 5 which became known as the Philadelphia chromosome. With advances in chromosomal banding techniques, the Philadelphia chromosome was identified as chromosome 22 with a deletion on the long arm linked with chromosome 9 as its t partner. Genetic-mapping techniques identified the breakpoint cluster region (BCR) and Abelson murine leukemia virus homolog (ABL) as the fusion partners in the t(9;22) product. 6 The chimeric bcr-abl protein drives abl kinase activity with the functional consequence of increased myeloid proliferation. In this proliferative state, additional pathogenic mutations develop, eventually leading to transformation into an acute leukemia. In the absence of treatment, the disease inevitably progresses. However, the development of tyrosine kinase inhibitors, such as imatinib mesylate, has led to remarkable improvements in survival. 7 Currently, CML is defined by the presence of the t(9;22), and the t has been shown to be both necessary and sufficient for disease. 7 century, when Dr Aldred Warthin described a family with multiple gastrointestinal cancers. Over 100 years later, epidemiological studies confirmed that HNPCC was inherited in an autosomal dominant manner.
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Genetic studies using microsatellite markers, which are short, usually noncoding DNA sequences containing tandem repeats of two to four nucleotides that are variable within the population and can serve as markers of inheritance, showed tight linkage of the disease with markers on the short arm of chromosome 2 (2p). 12 Researchers attempted to identify allelic loss on 2p (loss of heterozygosity (LOH)) as an explanation for tumorigenicity. While LOH was not seen, an interesting observation was made: the tumor cells contained multiple new microsatellite loci, which suggested impaired repair of repeated sequences. Subsequently, this process was termed microsatellite instability.
Concurrent investigations in yeast found mutated mismatch repair genes leading to microsatellite instability. These findings prompted a search for human homologs of the yeast mismatch repair genes, one of which was found on the short arm of 2p and is now known as MSH2. It is one of a handful of mismatch repair genes that can be mutated in HNPCC. 13 The familial nature of FAP was also recognized for decades before the first clues into the genetic basis of the disease were identified. In 1986, an interstitial deletion on the long arm of chromosome 5 (5q) was seen in a patient with FAP. Fine mapping at this locus ultimately led to the identification of the adenomatous polyposis coli (APC) gene. APC is now recognized as a pivotal tumor suppressor gene that is mutated early in the pathogenesis of most sporadic colorectal carcinomas.
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Identification of Cancer Genes In Vitro
Ras-Raf-MEK-ERK is one of the most commonly mutated pathways in human carcinomas. The first clues to this pathway's role in tumorigenesis came from in vitro biological assays in the early 1980s, when a genomic fragment derived from the DNA of a lung carcinoma cell line with homology to the Kirsten rat sarcoma virus was shown to transform fibroblasts. 15 Activating mutations in the KRAS gene have been found in up to 25% of human tumors and are instrumental in both tumor initiation and progression. 16 In addition, other members of the Ras-Raf-MEK-ERK pathway, promise to serve as important ancillary studies in lung cancer diagnosis.
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High-throughput Approaches to Cancer Gene Discovery
Currently, systematic analysis of cancer genomes by high-throughput methods is driving the discovery of important actors in tumorigenesis. • Currently, more than 1% of all human genes are implicated via mutation in cancer.
• Of every 100 women who carry the faulty version of the BRCA2 breast cancer gene, between 80 and 85% will develop breast cancer at some point in their life.
• By removing the gene SATB1 from cancer cells, researchers at
Lawrence Berkeley National Laboratory in California have been able to halt the progress of cancer cells and even return the cell to a noncancerous state.
• A mutation of the K-ras gene is present in approximately 40% of cancer patients. 
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